Introduction : The recent revision of the Declaration of Helsinki strengthened the ethical obligation to provide compensation for harm of research subjects. However, the actual status of providing compensation has rarely been disclosed, especially in the situation of investigator-initiated clinical trials(IITs). Objectives : To figure out the actual situation of compensation for injured subjects of IITs in Japan and to identify the necessary steps to fulfill the ethical obligation of compensation. Method : We conducted two types of surveys of compensation in IITs in Japan over the past five years. A : questionnaire survey delivered to 1,700 institutions on(1)number and paid amount of compensation cases ; number and amount of contract fees paid to insurance companies ; and (2) institutional management system of compensation cases. B : complementary survey to the item(1) of the survey A, at two institutions, on contract fees paid to and insurance paid from insurance companies. Result : In the survey A, we found only two cases of compensation provided, but could not find any serious cases claiming payment from insurance companies, although we could not exclude possibility of undisclosed cases. In the survey B, at the two institutions, a substantial amount of contract fees has been paid to insurance companies without claiming insurance payment ; however, the total amount for each institution is less than that expected for one case of a serious injury. Also we found that there remain several points to improve the institutional management system of compensation in IITs in Japan. Conclusion : To provide appropriate compensation for injured subjects of IITs, we need to develop an institutional management system, along with a system to gather statistical information of compensation cases, to achieve proper resource allocation. This system should also provide education for investigators and support staff to manage injury cases.
Introduction
The most recent revision in 2013 of the Declaration of Helsinki 1) , international ethical principles for medical research involving human subjects, strengthened the ethical obligation of researchers to provide compensation for subjects who are harmed as a result of participating in research. This is an ethical obligation to be assured not only for cases of negligence, but also for no-fault cases 2) . Pharmaceutical companies have about 20 years of experience of managing compensation cases since the establishment of international harmonization of Good Clinical Practice(GCP)guidelines in 1996 3) . Meanwhile, the actual status of compensation for injured subjects of investigator-initiated clinical trials (IITs) has rarely been reported. To fulfill this strengthened ethical obligation, an increasing number of academic institutions have come to make contracts with insurance companies in preparation for compensation cases. However, it is doubtful whether this kind of payment of the contract fees is a proper investment if there is no payment to be made for injured research subjects. There is a fundamental question whether any serious injury cases have happened in IITs in Japan or there are some undisclosed cases.
A previous questionnaire survey on the actual status of compensation for injured subjects of sponsor company-initiated clinical trials(SITs)aiming at new drug applications(NDAs)in Japan 4) found that 247 cases of 250 claims of compensation (99％)were awarded(The reasons of not awarding the 3 cases were not surveyed) ; this incidence of compensation, 250 cases, was from 32,318 subjects(0.8％)in 183 protocols which were completed from April 2009 to March 2010. Among these 250 cases, 229(0.7％)cases involved medical cost payment(which means to cover 30％ co-payment of patients) ; and 20 cases (0.06％)were monetary compensation paid for serious injury cases. In Japan there is no governmental compulsory insurance system for clinical trials and they provide compensation mostly according to the guideline by the Japan Pharmaceutical Industry Legal Affairs Association �JPILA� 5� , making contracts with private insurance companies to get insurance payment for some portion of their payments. This guideline was first published in 1999, using examples from the guidelines by the Association of British Pharmaceutical Industries�ABPI� 6� and revised in 2009 5� �Appendix, p. 225� and in 2015 7� . Available services of insurance companies in Japan can pay for monetary compensation for serious cases but do not cover medical costs. Therefore, Japanese pharmaceutical companies pay compensation for medical costs at their own expense.
The above mentioned survey excluded phaseⅠstudies on healthy volunteers, therefore, all the cases are of patient research participants. It also did not cover IITs. For this reason, we conducted this study to determine the actual situation of providing compensation for injured subjects of IITs in Japan, focusing on statistics of compensation cases and contract fees paid to and insurance paid from insurance companies, as well as the institutional management system of compensation cases. We did this in order to identify the necessary steps to fulfill the ethical obligation of compensation for injured research subjects of IITs.
Method
We conducted the following two types of surveys A and B on compensation for injured subjects of IITs in Japan. There are two regulatory categories of IITs in Japan : IITs aiming at NDAs regulated by the Good Clinical Practice�GCP�Ordinance under the Pharmaceutical Affairs Law ; and IITs regulated by the governmental Ethical Guidelines for Clinical Research �These laws and guidelines were revised and their titles were changed after the target period of this survey�. Both regulations require investigators to prepare for compensation for injured subjects.
Survey A
Web-based questionnaire survey focusing on : �1� Number of cases in which compensation was provided to injured subjects, along with the number and amount of contract fees paid to, and insurance paid from insurance companies. �2� Institutional management system of compensation cases, focusing on institutional policy ; mechanism to manage compensation cases and its experience of management of the cases.
The questionnaire was disseminated by the Center for Clinical Trials, Japan Medical Association to the 1,700 registered member medical／academic institutions of the Large-scale Clinical Trials Network. We asked about IITs which were completed during the past five years�fiscal year�FY�2009 to 2013�. Responses were accepted from October 20 to December 25, 2014.
Survey B
To complement the study results of the item �1� of the above survey A, we gathered statistical information focusing on contract fees paid to and insurance paid from insurance companies, at the two institutions of the authors �National Institute of Radiological Sciences and Hamamatsu University School of Medicine� on IITs which started from FY 2010 to 2014. In the case of the National Institute of Radiological Sciences, the data was limited to insurance contracts for similar brain imaging studies using PET �positron emission tomogra- 
Results

Results of survey A
(1) Number of cases in which compensation was provided to injured subjects, along with the number and amount of contract fees paid to, and insurance paid from insurance companies Among 1,700 members who received the information of the web-based survey, 75 institutions responded and submitted their answers. Among these 75 institutions, 73 have not experienced the cases in which compensation was provided to injured subjects of IITs, while the 2 have such experiences
8�
. One of these 2 institutions answered that there were 2 cases of compensation in FY 2010 ; the total amount of payment for these 2 cases was 500,000 Japanese yen�JPY��4,026 United States Dollars : USD�. Another institution did not provide an answer about the amount of the payment.
We could not obtain any answers to the questionnaire items about the number and amount of contract fees paid to, and insurance paid from insurance companies.
(2) Institutional management system of compensation cases, focusing on institutional policy; mechanism to manage compensation cases and its experience of management of the cases�Detailed results are in Figure 1� .
Among 75 institutions, 24�32％�answered that they follow the JPILA guideline, which is for SITs. There were also 8�11％� institutions which follow their own institutional policy. Among these 8 institutions, 5 have some written policy 8� but 3 do not have any written one. Meanwhile, 48 �64％� did not have a specific policy for compensation, except the policy to follow governmental Ethical Guidelines for Clinical Research.
There were 12�16％�institutions which have a committee to define the appropriateness of providing compensation according to each case. For 10 of these, this means that institutional review board �IRB� or ethics commit �EC� takes the role of this committee ; 63 �84％� answered that they do not have such a committee. Only 3 institutions answered that the above committee has a member who is a lawyer. Among these 12 institutions, 4 answered that they have experience of discussing about compensation issues not limited to actual cases, among which 2 discussed 2 topics ; 1 discussed 10 topics, and 1 discussed 50 topics. These 12 institutions do not include the above mentioned institutions which have experience in providing compensation to injured subjects, which means that all of these cases of discussion may be not for actual cases ; whereas the above mentioned 2 cases of providing compensation might not be based on discussion of some committee which decided the appropriateness of providing compensation.
Results of survey B
(1) Statistics of the amount of contract fees paid to and insurance paid from insurance companies at the two surveyed institutions Table 1 shows the statistics of the amount of contract fees paid to insurance companies for the preparation of injury cases of IITs, at the above mentioned�Program�and Hamamatsu University At the Program, the total amount of the contract fees paid to insurance companies was 7,765,750 JPY for 33 protocols. The average unit fee was 8,745 JPY per one subject and there was not a notable difference of unit fee among the protocols because the types of studies were similar PET brain imaging studies in this Program. In 2015 this Program changed their type of contract with the insurance company from a one-by-one contract for each protocol to that of a comprehensive contract to cover all of the defined types of protocols of this Program.
During the surveyed term, there has been no case of the need to pay compensation to injured subjects, in terms both of monetary compensation for serious injury and payment for medical costs. All the information about contracts with insurance companies and injury cases, if there are any, is managed by one research support office, the Clinical Research Support Unit, which one of the authors is affiliated to.
At the Hamamatsu University School of Medicine, the total amount of the contract fees paid to insurance companies was 7,844,705 JPY for 68 protocols. The average unit fee was 3,190 JPY per one subject ranging from 825 JPY, the lowest, to 57,880 JPY, the highest. Because this institution is a general hospital, there is a wide variety of studies from low risk to high risk.
This institution does not have a one-stop management office to deal with injury cases as well as contracts with insurance companies. Therefore, we cannot obtain accurate statistical information about the number of compensation cases, but it was confirmed that there were no cases involving claims to the insurance company for payment. We did obtain the information of two cases in which compensation was paid for medical costs, but could not determine if there were any other cases.
(2) Statistics of number of contracts of the two surveyed institutions with each available insurance companies Figure 2 shows the numbers of contracts with insurance companies for clinical trials of this Program along with the Hamamatsu University School of Medicine. In the beginning, since the time when the 2007 revision of the governmental guideline came to require investigator-initiated clinical research using drugs or devices to prepare for compensation, there was only one insurance company that provided compensation service for clinical research. However, since 2012, three insurance companies came to provide such a service. There is not much difference in the types of compensation service provided among these three companies. Basically all of these services include monetary compensation but do not include medical costs.
Discussion
Survey A
Generalizability of survey A is limited as the surveyed population is only a small part and the response rate of this questionnaire survey is very low. This is partially because most of the medical／academic institutions in Japan do not have a onestop office to manage the issue of compensation. From these reasons, we have to consider the possibility of undisclosed cases of injuries, including the cases of�unofficial�payment of compensation. What is true is that we have not obtained any publicly available information of compensation payment to seriously injured subjects claiming payment from any insurance company. The two cases of paying compensation found in survey A may be for medical costs, in terms of the paid amount. Most of the Japanese insurance companies do not pay for medical costs at this moment so it should be paid by the medical institution.
From the second part of survey A, we can assume that the institutional management system for compensation cases has not been sufficiently established in Japanese medical／academic institutions 8) . To provide compensation appropriately, we need institutional policy development, as well as a system of management (e.g., procedures of consulting with injured subjects, and providing compensation payment)and assessment (e.g., assessing causal relationship and grade of injury to define the amount of compensation)of actual cases.
Survey B
Survey B suggests that a substantial amount of contract fees has been paid to insurance companies. Meanwhile, we could not find any serious compensation cases involving claims to insurance companies for payment, although we cannot exclude the possibility of undisclosed cases of injuries. An interesting finding is that the total amount of contract fees of each of the two institutions is far less than the amount which should be paid if only one serious injury case happened to a young healthy volunteer ; or to cover only one case of elderly patient, according to the JPILA guideline (Table 1 and Appendix). This kind of balance of total of payments of contract fees to insurance companies and incidence rate of compensation cases and corresponding amount of money to be paid to injured subjects should be studied in future with larger number of cases of clinical trials.
Considerations on survey A and B
In addition to the above mentioned limitation of these surveys, there are some possible reasons of difficulty of obtaining information of compensation cases :
(1) Academic clinical research with patient subjects tends to focus on typical two areas : (a)rare, intractable diseases where adverse events are difficult to be distinguished from the natural course of deterioration of diseases or inevitable worsening ; and (b)post-marketing clinical trials where risk of research-specific related injury is low and it may be possible to get payment from �Relief System for Adverse Health Effects�which includes �Adverse Drug Reaction (ADR) Relief System� . This system covers compensation for ADRs of marketed drugs and is managed by the governmental body Pharmaceuticals and Medical Devices Agency (PMDA), based on legally defined funds contributed by pharmaceutical companies ; (2) Academic investigators have not been well trained to find and report research-related adverse events and there are not enough clinical research coordinators(CRCs)assigned to support IITs ; additionally, institutional policy and the management system for compensation is inefficient in the Japanese research community to identify and manage the cases necessary to provide compensation ; (3) As for the case of the experimental studies on healthy volunteers, only limited academic institutions, including the above mentioned Program and Hamamatsu University School of Medicine, conduct such studies, where extremely careful conduct is required. Additionally, it is very difficult to hide the cases of serious injuries of healthy volunteers. Therefore, we assume that serious injury cases have not happened in IITs in Japan until now. However, we still cannot exclude the possibility of undisclosed cases and can never exclude the future possibility of occurrence, which is conceivable from previous reports 9−11) . In contrast to the absence of information of compensation paid to injured subjects of IITs in Japan, increasing and substantial amounts of contract fees have been paid to insurance companies. Increasing numbers of academic investigators come to make contracts with insurance companies as it is necessary for passing the IRB／ECs review ; and they feel it necessary to prepare for serious injury cases which may happen sometimes in future. However, it is ironic that payment from most of the Japanese insurance companies do not cover medical costs although the incidence of cases which need medical cost is higher than the incidence of serious injury cases. Available insurance services in Japan cover only large amounts of compensation payment for serious injury cases. However, if an institution requests an insurance company for payment, the contract fee with this institution is raised according to an established theory of insurance. This does not necessarily mean that insurance companies only gain profit. The market size of compensation service for IITs is very small and this service has only a short history. According to the insurance companies, a substantial portion of money gained as contract fees has been paid as personnel expenses for management of these contracts. Most importantly, survey B found that the total amount of contract fees paid during five years does not cover the necessary amount of compensation for serious injury cases which may happen in future. A comprehensive contract with an insurance company covering all the protocols in one program �such as the contract in 2015 of the above mentioned�Program� � ; one department ; or one university hospital, instead of one-by-one contract for each protocol, may be a partial solution. The merit of this type of contract is to decrease the amount of administrative procedures and personnel expenditure which is taken for each contract for each protocol. Such expenditures should be switched to appropriate compensation payment to injured subjects, including the medical cost.
Ideally, the direction to go ahead would be to establish a public insurance system based on a legal framework, which some of the European countries have already achieved
9�
. Such a legally defined system would be necessary for a fair and proper development of funding and fair allocation of compensation based on unbiased statistical risk analysis.
Conclusions
As the conclusions, we identified the necessary steps to fulfill ethical obligation of appropriate compensation for injured subjects of IITs as follows : �1� It is necessary for clinical research institutions to develop a policy and system for management and assessment of compensation cases. �2� This system should include a one-stop office not only for management and assessment, but also information gathering of compensation cases, which is necessary for statistical risk analysis needed for appropriate financial resource allocation for the insurance mechanism. �3� It is also necessary to provide education for investigators and support staff to identify and manage injury cases which need to be compensated. Such education should be provided by an institutional management system under the institutional policy described in�1�and�2�. �4� Comprehensive contracts with insurance companies instead of a one-by-one contract for each study protocol may be one possible solution for more appropriate financial and personnel resource allocation. �5� Ideally, more appropriate compensation to fulfill our ethical obligation would be achieved by means of a public insurance system based on a legal framework.
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Appendix-Table 1 Comparison of policies between ABPI（Association of British Pharmaceutical Industries）and JPILA（Japan
Pharmaceutical Industry Legal Affairs Association)
○Yes.（1.1)
ABPI guideline
○Yes.（1-1)
JPILA guideline
Exclusion of specific classes of drugs.
（Not applicable, because it is defined in each study protocol.)
×Not covered by the guideline.（4-3-1)
×Not covered by the guideline.（2.3) Injury caused by marketed drug. 9 △In principle not compensated, but may be compensated in specific cases, e.g. aggravation caused by placebo use during washout period.（3-2) ×Not compensated.（3.3) To fail to get therapeutic benefit due to receiving placebo.
Agreement by company to abide by the guidelines does not affect the right of the volunteer pursue a legal remedy. Limitation of compensation according to benefit／risk（severity of disease, probability of events), and consent of the volunteers. （Not applicable, because it is defined in each study protocol.)
Range and limitation
△Only medical cost is compensated in cases of carcinostatic substances, and immunosuppressive agents, but considering the benefit／risk, monetary compensation may be provided
＊3
.（4-3-2)
-Not mentioned. 12 ○Yes.（1-3) ○Yes.（1.2) Injury resulting from the clinical trial （study drug or procedure defined in the protocol）could be compensated. 7 ○Yes.（1-1) ○Yes.（1.7) Study subject（volunteer）does not have to prove negligence and／or causality. 11 ○Yes.（1-2) △Yes, but the volunteers will normally be asked to accept that any payment made under the Guidelines will be in full settlement of their claims.（5.3) 6 ×Not compensated as it is the liability of the third party.（2-2,3) ×Not compensated.（3.4.2) Wrongful or negligent act of a third party, including a doctorʼs failure to deal adequately with an injury. (continued) Appendix- Table 1 ×Not compensated in case of patient volunteer （1.4） ；For healthy volunteer, any injury should be compensated （There are other guidelines specific to healthy volunteer).
Less serious, curable injury. ○Volunteer should claim to the company via the investigator, providing an authority for the company to review medical record. Company should consider the claim expeditiously.（5.1) Procedures for management of claims. 12（See footnote ＊2 ) ○Details of the compensation system should be explained to the volunteer using an outlined paper which should be provided to the volunteer along with the informed consent documents.（4-2) △Company should encourage the investigator to make clear to the participating volunteers that the trial is being conducted in accordance with the guidelines and that copy of the guidelines should be made available when requested.（5.4) Explanation to volunteers at the time of informed consent.
Procedures and arbitration
12 ○Medical cost and monetary compensation should be compensated, calculated based on the other governmental system of compensating injuries
○The amount of compensation should be appropriate to the nature, severity and persistence of the injury and should be consistent with the amount awarded for similar injuries by an English Court in cases of legal liability.（4.1) Serious and／or irreversible injury or death.
12 ○Only medical cost should be compensated, calculated based on other governmental system
＊4
.（4-1-1, 2) Injury caused by an incidental accident, not due to the administration of the investigational drug.
○compensation is possible △case by case ×not to be compensated（For the items in�Procedures and arbitration� ：○enough △partially enough ×not enough) 7 ○Independent expert（s）mutually agreed to by the volunteer and the sponsor may be consulted in case of any controversy relating to the causal relationship or the severity of injury or disability.（6-1) ○Independent expert（s）mutually acceptable to the volunteer and the sponsor may be consulted in case of any controversy relating to the level of compensation.（4.3) Dispute resolution. 9 ○Payment for medical expense and medical allowance shall start promptly to relieve volunteer. Then payment for monetary compensation shall be discussed for assessment of the causal relationship.（5-2,3) 12 △In principle not compensated, but may be considered whether or not to be compensated in specific cases, e.g., aggravation compared to the baseline which could not have occurred without the participation in the clinical trial. （3-1) ×Not compensated.（3.1) Failure of the study drug to have the intended effect. 11 ×Not compensated.（2-1) -Not mentioned.
＊1 Simply described outlines in this table do not cover all of the description in both guidelines. ABPI has separate compensation guidelines for patients and for healthy volunteers, whereas JPILA includes both in one guideline, making difference between these two areas. We compared these two guidelines focusing on policies relating to compensation for patient volunteers, while adding some specific issues for healthy volunteers in the footnotes.
＊2
In our previous study published in 2014 4) , among the 68 member companies of the Japan Pharmaceutical Manufacturers Association （JPMA）to whom the questionnaire survey was delivered, 44 companies responded. Of these 44 companies, 12 companies provided documents（which was in 2010）outlining their policy on compensation, which they provide to volunteers along with the informed consent documents（ICDs).
＊3
In Japan,�Adverse Drug Reaction Relief System（ADR Relief System） �for marketed drug excludes carcinostatic substances, and immunosuppressive agents. The 2009 revision of JPILA guidelines states that the compensation policy for adverse reactions of carcinostatic substances should be defined in each protocol based on a benefit／risk assessment.
＊4 JPILA guidelines suggest that the amount of compensation for patient volunteers should be calculated based on the rules of the�ADR Relief System�which is the system for compensating injuries caused by marketed drugs. Listed below are the amounts of compensation for 2009 fiscal year.（This is because our previous survey was of the protocols completed this fiscal year. These amounts may be changed each year considering environmental changes, such as price index or market interest rates.)
For healthy volunteers, the amount of compensation for treatment of injury is the same as those for patient volunteers. However, in cases where health insurance is not available, e.g., in the cases of injuries at the phaseⅠclinic, sponsor has to pay 100％ of the medical cost. The amount of monetary compensation for the cases of death or permanent disability is calculated based on the rules of the�Law for Workmenʼs Compensation�or the�Relief System for Injury to Health with Vaccination� , which provides compensation amounts higher than those provided under the compensation system for patient volunteers（for example, in the case of�category 1�injury shown below, the difference is approximately 1.8 times compared to the case of patient volunteer).
Under the�ADR Relief System� , the amount of monetary compensation is calculated based on the post-injury classifications. For patient volunteers, compensation is limited to category 1 and 2 injuries, where ordinary life is substantially limited or more seriously affected. For healthy volunteers, almost all irreversible injuries are compensated, from category 1 to 14 injuries defined in the�Law for Workmenʼs Compensation�or category 1 to 5 defined in the�Relief System for Injury to Health with Vaccination� .
Compensation for medical cost under theADR Relief System
-Medical expenses：The amount of patientʼs copayment part which is 30％ of the total medical expense for necessary medical care, excluding the 70％ which is covered by the public health insurance（In case health insurance is not available, sponsor shall pay 100％ of the medical cost). -Medical allowance：For miscellaneous expenditures related to medical care or hospitalization, such as transportation expenses, incidental costs, etc.. （1) Volunteers who receive medical care for three or more days in a month（in cases when patients cannot be in the hospital because of some reason）shall be paid JPY（Japanese Yen）35,800 per month, and those who receive less than three days medical care in a month shall be paid JPY 33,800 per month. （2) Volunteers who have been hospitalized for eight or more days in a month shall be paid JPY 35,800 per month and those who are hospitalized for less than eight days in a month shall be paid JPY 33,800 per month. （3) Those who need both medical care and hospitalization shall be paid JPY 35,800 per month.
Monetary compensation for disability or death under theADR Relief System
（JPILA guidelines suggest that the following pension defined under the�ADR Relief System�should be paid in full by multiplying it with the present value coefficient, Leibnizʼs coefficient corresponding to the each period（ ＊＊ ), based on legally permissible interest rate （5％）at the time of the occurrence of the injury：) -Disability pension： （1) category 1：JPY 2,720,400 annually（JPY 226,700 per month) （2) category 2：JPY 2,175,600 annually（JPY 181,300 per month) （ ＊＊ mean life expectancy.) -Pension for raising children handicapped by a medical injury （1) category 1：JPY 850,800 annually（JPY 70,900 per month) （2) category 2：JPY 680,400 annually（JPY 56,700 per month) （ ＊＊ The years until the child becomes an adult（18 years old). When the child becomes an adult（18 years old), monetary compensation for disability shall be paid in full by multiplying disability pension with the present value coefficient corresponding to the mean life expectancy.) -Payments in cases of death： （1) Bereaved family pension due to death of a volunteer who is a breadwinner in the family：JPY 2,378,400 annually（JPY 198,200 per month), up to 10 years （2) Lump-sum benefits for the bereaved family due to death of a volunteer who is not a breadwinner in the family：JPY 7,135,200 （3) Funeral expenses：JPY 201,000 （ ＊＊ （1）should be lump-sum payment corresponding to ten years； （2）should be paid same as in the case of�ADR Relief System� ； （3）should be paid same as that above, whether or not the volunteer patient is the breadwinner in the family.) 
